IONS

NASDAQ · Biotechnology

Ionis Pharmaceuticals Inc

Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$76.52

+0.53 (+0.70%)

As of Jun 24, 9:43 PM ET ·

IONS News1 articles

Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.